Sage Journals: Discover world-class research

Abstract

Regulatory agencies vary widely in their classification of FMT, with significant impact on patient access. This article conducts a global survey of national regulations and collates existing FMT classification statuses, ultimately suggesting that the human cell and tissue product designation best fits FMT's characteristics and that definitional objectives to that classification may be overcome.

Get full access to this article

View all access options for this article.

References

Kelly

et al., “Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook,” Gastroenterology 149, no. 1 (2015): 223-227.

J.L.

Rosner

, “Ten Times More Microbial Cells than Body Cells in Humans?” Microbe Magazine 9, no. 2 (2014): 47–47 at 47.

M.E., “What Is the Human Microbiome, Exactly?” Nautilus, available at <http://nautil.us/blog/what-is-the-human-microbiome-exactly> (last visited July 26, 2019).

C.M.

Surawicz

et al., “Guidelines for Diagnosis, Treatment and Prevention of Clostridium difficile Infections,” The American Journal of Gastroenterology 108, no. 4 (2013): 478–498 at 478.

See Surawicz et al., supra note 4 at 478;

J.Y.

Chang

et al., “Decreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile –Associated Diarrhea,” The Journal of Infectious Diseases 197, no. 3 (2008): 435–438 at 437.

See Surawicz et al., supra note 4 at 486.

Cammarota

et al., “Randomised Clinical Trial: Faecal Micro-biota Transplantation by Colonoscopy vs. Vancomycin for the Treatment of Recurrent Clostridium difficile Infection,” Alimentary Pharmacology and Therapeutics 41, no. 8 (2017): 835-843 at 840.

See Surawicz et al., supra note 4 at 478.

Desai

et al., “Epidemiological and Economic Burden of Clostridium Difficile in the United States: Estimates From A Modeling Approach,” BMC Infectious Diseases 16, no. 1 (2016): 1-10 at 1.

10.

Centers for Disease Control and Prevention, “Antibiotic Resistance Threats in the United States,” (2013) at 51.

11.

F.C.

Lessa

et al., “Burden of Clostridium difficile Infection in the United States,” New England Journal of Medicine 372, no. 9 (2015): 825–834 at 825.

12.

See Surawicz et al., supra note 4 at 486.

13.

Maroo and

J.T.

Lamont , “Recurrent Clostridium difficile,” Gastroenterology 130, no. 4 (2006): 1311–1316 at 1311.

14.

M.A.

Olsen

et al., “Recurrent Clostridium difficile Infection is Associated with Increased Mortality,” Clinical Microbiology and Infection 21, no. 2 (2015): 164-170 at 170.

15.

See Centers for Disease Control and Prevention, supra note 10 at 51.

16.

S.J.

Dancer

, “The Role of Environmental Cleaning in the Control of Hospital-Acquired Infection,” Journal of Hospital Infection 73, no. 4 (2009): 378-385 at 380-381.

17.

E.G.

Pamer

, “Resurrecting the Intestinal Microbiota to Combat Antibiotic-Resistant Pathogens,” Science 352, no. 6285 (2016): 535–538 at 535.

18.

van Nood

et al., “Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile,” New England Journal of Medicine 368, no 5 (2013): 407–415 at 414.

19.

See Z. Kassam, C.H. Lee, Y. Yuan, and R.H. Hunt, supra note 7 at 505; see G. Cammarota et al., supra note 7 at 840.

20.

G.G.

Konijeti ,

Sauk ,

M.G.

Shrime ,

Gupta , and

A.N.

Ananthakrishnan , “Cost-effectiveness of Competing Strategies for Management of Recurrent Clostridium difficile Infection: A Decision Analysis,” Clinical Infectious Diseases 58, no. 11 (2014): 1507–1514 at 1507.

21.

C.H.

Lee

et al., “Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients with Recurrent Clostridium difficile Infection: A Randomized Clinical Trial,” Journal of the American Medical Association 315, no. 2 (2016): 142-149 at 142.

22.

Wang

et al., “Systematic Review: Adverse Events of Fecal Microbiota Transplantation,” PLOS ONE 11, no. 8 (2016), available at <https://dx.plos.org/10.1371/journal.pone.0161174> (last visited April 15, 2019).

23.

S.M.

Collins ,

Kassam , and

Bercik , “The Adoptive Transfer of Behavioral Phenotype Via the Intestinal Microbiota: Experimental Evidence and Clinical Implications,” Current Opinion in Microbiology 16, no. 3 (2013): 240–245 at 240.

24.

Khoruts

et al., “The Impact of Regulatory Policies on the Future of Fecal Microbiota Transplantation,” Journal of Law, Medicine & Ethics 47, no. 4 (2019): 482-504.

25.

C.A.

Edelstein ,

Kassam ,

Daw ,

M.B

Smith , and

C.R.

Kelly , “The Regulation of Fecal Microbiota for Transplantation: An International Perspective for Policy and Public Health,” Clinical Research and Regulatory Affairs 32, no. 3 (2015): 101-109 at 102.

26.

C.A.

Lozupone ,

J.I

Stombaugh ,

J. I

Gordon ,

J. K

Jansson , and

Knight , “Diversity, Stability and Resilience of the Human Gut Microbiota,” Nature 489, no. 7415 (2012): 220–230.

27.

See C.A. Edelstein, Z. Kassam, J. Daw, M.B Smith, and C.R. Kelly, supra note 25 at 107.

28.

Khoruts et al., supra note 24.

29.

Eakin

, “The Excrement Experiment,” The New Yorker, December 1, 2014, available at <https://www.newyorker.com/magazine/2014/12/01/excrement-experiment> (last visited April 17, 2019).

30.

See Khoruts et al., supra note 24.

31.

M.B.

Smith ,

Kelly , and

E.J.

Alm , “Policy: How to Regulate Faecal Transplants,” Nature News 506, no. 7488 (2014): 290-291.

32.

21 § CFR 1271.3 (2001).

33.

Megerlin ,

Fouassier ,

Lopert , and

Bourlioux , “Faecal Microbiota Transplantation: A Sui Generis Biological Drug, Not a Tissue,” Annales Pharmaceutiques Françaises 72, no. 4 (2014): 217–220.

34.

Therapeutic Goods Administration, Options for the Regulation of Faecal Microbiota Transplantation Material (January 2019).

35.

Professor Thomas Borody, The Centre for Digestive Diseases, available at <https://centrefordigestivediseases.com/about-us/professor-thomas-borody/> (last accessed April 30, 2019).

36.

Email communication between the author and P. Stadelmann of Swissmedic (April 8, 2019).

37.

K.E.

Burke and

J.T

Lamont , “Clostridium difficile Infection: A Worldwide Disease,” Gut Liver 8, no. 1 (2014): 1–6.

38.

Center for Biologics Evaluation and Research, Guidance for Industry: Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies (May 2013) [hereinafter cited as CBER Report July 2013].

39.

See E. van Nood et al., supra note 18.

40.

See CBER Report July 2013, supra note 38.

41.

Id.

42.

Center for Biologics Evaluation and Research, Draft Guidance for Industry: Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies (March 2014) [hereinafter cited as CBER Report March 2014].

43.

44.

D.E.

Hoffmann

et al., “Improving Regulation of Microbiota Transplants,” Science 358, no. 3639 (2017): 1390-1391; See C.A. Edelstein, Z. Kassam, J. Daw, M.B Smith, and C.R. Kelly, supra note 25.

45.

21 § CFR 1271.3 (2001).

46.

See R.E. Sachs and C.E. Edelstein, supra note 44 at 410-411.

47.

Id. at 411.

48.

See CBER Report July 2013, supra note 38.

49.

See C.M. Surawicz et al., supra note 4 at 479.

50.

See C. Kelly et al., supra note 1 at 224.

51.

Moore ,

Rodriguez , and

J.S.

Bakken , “Fecal Microbiota Transplantation: A Practical Update for the Infectious Disease Specialist,” Clinical Infectious Diseases 58, no. 4 (2014): 541–545 at 542.

52.

Panchal

et al., “Scaling Access to Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection in the United States: A Geospatial Time-Series Analysis from 2013 to 2017,” Gastroenterology Journal 154, no. 6 Supplement 1 (2018): S-190-S-191.

53.

See OpenBiome, Press Release, In Its Fifth Year, OpenBiome Reaches Major Milestone In Expanding FMT Access: 40,000 Treatments Shipped, October 5, 2018), available at <https://www.openbiome.org/press-releases/2018/10/5/in-its-fifth-year-openbiome-reaches-major-milestone-in-expanding-fmt-access-40000-treatments-shipped> (last visited July 27, 2019).

54.

P. N.

Ossorio and

Zhou , “FMT and Microbial Medical Products: Generating High-Quality Evidence through Good Governance,” Journal of Law, Medicine & Ethics 47, no. 4 (2019): 505-523, referencing over 300 studies in clinicaltrials.gov.

55.

Regulatory, OpenBiome, available at <https://www.openbiome.org/regulatory> (last visited July 26, 2019).

56.

Health Canada, Fecal Microbiota Therapy Used in the Treatment of Clostridium difficile Infection Not Responsive to Conventional Therapies, March 2015

57.

Moayyedi ,

J.K

Marshall ,

Yuan , and

Hunt , “Canadian Association of Gastroenterology Position Statement: Fecal Microbiota Transplant Therapy,” Canadian Journal of Gastroenterology and Hepatology 28, no. 2 (2014): 66–68 at 67.

58.

V.G.

Loo

et al., “Association of Medical Microbiology and Infectious Disease Canada Treatment Practice Guidelines for Clostridium difficile Infection,” Official Journal of the Association of Medical Microbiology and Infectious Disease Canada 3, no. 2 (2018): 71–92 at 74.

59.

Sheitoyan-Pesant

et al., “Clinical and Healthcare Burden of Multiple Recurrences of Clostridium difficile Infection,” Clinical Infectious Diseases 62, no. 5 (2016): 574–580 at 576.

60.

Edelstein ,

J.R.

Daw , and

Kassam , “Seeking Safe Stool: Canada Needs a Universal Donor Model,” Canadian Medical Association Journal 188, no. 17-18 (2016): E431–E432 at E432.

61.

Id at E432.

62.

Competent Authorities for Tissues and Cells, Meeting of the Competent Authorities for Tissues and Cells Summary Report, June 2012.

63.

Competent Authorities on Substances of Human Origin Expert Group, Meeting of the Competent Authorities for Tissues and Cells Summary Report, June 2014.

64.

S.B.

Debast ,

M.P.

Bauer , and

E.J.

Kuijper , “European Society of Clinical Microbiology and Infectious Diseases: Update of the Treatment Guidance Document for Clostridium difficile Infection,” Clinical Microbiology and Infection 20, Supplement 2 (2014): 1–26 at 18.

65.

Cammarota

et al., “European Consensus Conference on Faecal Microbiota Transplantation in Clinical Practice,” Gut 66, no. 4 (2017): 569–580 at 570.

66.

Z.H.

Davidovics

et al., “Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection and Other Conditions in Children: A Joint Position Paper from the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition,” Journal of Pediatric Gastroenterology and Nutrition 68, no 1 (2019): 130–143 at 139.

67.

P.K.

Kump ,

Krause ,

Allerberger , and

Högenauer , “Faecal Microbiota Transplantation — the Austrian Approach,” Clinical Microbiology and Infection 20, no. 11 (2014): 1106–1111 at 1107.

68.

Email communication between the author and M. Behounek of the Bureau of the Federal Office for Safety in Health Care, May 3, 2019.

69.

Kump

et al., “Empfehlungen zur Anwendung der fäkalen Mikrobiotatransplantation Stuhltransplantation: Konsensus der Österreichischen Gesellschaft für Gastroenterologie und Hepatologie,” Zeitschrift für Gastroenterologie 52, no. 12 (2014): 1485–1492.

70.

Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten, Advies van de Hoge Gezondheidsraad nr. 9202: Aanbevelingen Betreffende de Therapeutische Indica-ties, dePprocedures, de Veiligheid en deKkwaliteit van de Transplantatie van Fecaal Materiaal, March 2014.

71.

Id.

72.

Email communication between the author and R. Van Gelder of the Federal Agency for Medicines and Health Products, May 3, 2019.

73.

Email communication between the author and L. Hemmingsen of the Danish Medicines Agency, June 25, 2019.

74.

Email communication between the author and T. Suvi of the State Agency of Medicines, April 12, 2019.

75.

Email communication between the author and K. Pellas of the Finnish Medicines Agency April 11, 2019.

76.

Lahtinen

et al., Faecal Microbiota Transplantation in Patients with Clostridium difficile and Significant Comorbidities as well as in Patients with New Indications: A Case Series,” World Journal of Gastroenterology 23, no. 39 (2017): 7174-7184 at 7176.

77.

L'Agence National de Securite du Medicament et des Produits, La Transplantation de Microbiote Fécal et Son Encadrement dans les Essais Cliniques, March 2014.

78.

Sokol

et al., “Faecal Microbiota Transplantation in Recurrent Clostridium difficile Infection: Recommendations from the French Group of Faecal Microbiota Transplantation,” Digestive and Liver Disease 48, no. 3 (2016): 242–247.

79.

Email communication between the author and M. Müllers of the Federal Institute for Drugs and Medical Devices, April 2, 2019.

80.

Email communication between the author and S. Cudmore of University College Cork, April 4, 2016.

81.

A.R.

Prior ,

Kevans ,

McDowell ,

Cudmore , and

Fitzpatrick , “Treatment of Clostridium difficile infection: A National Survey of Clinician Recommendations and the Use of Faecal Microbiota Transplantation,” Journal of Hospital Infection 95, no. 4 (2017): 438–441 at 440.

82.

Il Presidente in Qualita' di Comissario ad Acta, Recepimento de Programma Nazionale Trapianto di Microbiota Fecale: Aspetti Regolatori, Clinici e Organizzativi, 2018.

83.

Email communication between the author and H. Vella of the Medicines Authority of Malta, April 25, 2019.

84.

Email communication between the author at F. van Linden of the Health Care and Youth Inspectorate, June 3, 2019.

85.

E.M.

Terveer

et al., “How to: Establish and Run a Stool Bank,” Clinical Microbiology and Infection 23, no. 12 (2017): 924–930 at 926.

86.

Id. at 929.

87.

Email communication between the author and K. Odlo Høye of the Norwegian Medicines Agency, April 25, 2019.

88.

Email communication between the author and I. Wojtyra of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, April 15, 2019.

89.

Email communication between the author and L. Leite of the National Authority of Medicines and Health Products, I.P., May 30, 2019.

90.

Email communication between the author and a representative of the Agency for Medicinal Products and Medical Devices of the Republic of Slovenia, April 16, 2019.

91.

Reigadas

et al., “Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection: Experience, Protocol, and Results,” Revista Espanola De Quimioterapia: Publicacion Oficial De La Sociedad Espanola De Quimioterapia 31, no. 5 (2018): 411–418.

92.

A.G.

Garcia de Paredes

et al., “Trasplante de Microbiota Fecal por Colonoscopia para el Tratamiento de la Infección Recurrente por Clostridium difficile,” Asociación Española de Gastroenterología (2019).

93.

Email communication between the author and P. Stadel-mann, supra note 36.

94.

Searching for a clinical trial, Kofam, available at <https://www.kofam.ch/en/snctp-portal/searching-for-a-clinical-trial/?sid=49029> (last visited April 30, 2019).

95.

Medicines Borderline Section, Faecal Microbiota Transplantation (FMT): MHRA's Position, June 2015.

96.

Regulation of faecal microbiota transplant (June 3, 2015), Human Tissue Authority, available at <https://www.hta.gov.uk/policies/regulation-faecal-microbiota-transplant> (last visited March 7, 2019).

97.

National Institute for Health and Care Excellence, Faecal Microbiota Transplant for Recurrent Clostridium difficile Infection: Interventional Procedures Guidance, March 27, 2014.

98.

Public Health England, Updated Guidance on the Management and Treatment of Clostridium difficile Infection, May 2013.

99.

B.H

Mullish

et al., “The Use of Faecal Microbiota Transplant as Treatment for Recurrent or Refractory Clostridium difficile Infection and Other Potential Indications: Joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) Guidelines,” Gut 67, no. 11 (2018): 1920–1941 at 1920-1921.

100.

M.N.

Quraishi

et al., “National Survey of Practice of Faecal Microbiota Transplantation for Clostridium difficile Infection in the UK,” Journal of Hospital Infection 95, no. 4 (2017): 444–445.

101.

Email communication between the author and T. O'Reilly of the Therapeutic Goods Association, November 30, 2015.

102.

See Therapeutic Goods Administration, supra note 34.

103.

Gastroenterological Society of Australia, Position Statement on Faecal Microbiota Transplant (FMT), September 2015, available at <http://www.gesa.org.au/public/13/files/GESA%20position%20statement%20FMT%20FAM%20JMA%20SPC%2020170426.pdf> (last visited July 28, 2019).

104.

J.A.

Trubiano

et al., “Australasian Society of Infectious Diseases Updated Guidelines for the Management of Clostridium difficile Infection in Adults and Children in Australia and New Zealand: CDI Management Guidelines,” Internal Medicine Journal 46, no. 4 (2016): 479–493 at 485.

105.

See Professor Thomas Borody, supra note 35.

106.

See Gastroenterological Society of Australia, supra note 103.

107.

Email communication between the author and S. Reader of the Medicines and Medical Devices Safety Authority, December 3, 2015.

108.

Email communication between the author and M. Chan of the Department of Health, April 9, 2019.

109.

Information for Patients | Overview, Asia Microbiota Bank, available at <http://asiabiobank.com/for-patients/overview/> (last visited April 30, 2019).

110.

Medical Directorate, “Stool Transplant,” May 29, 2017.

111.

Email communication between the author and a representative of the Therapeutic Products Branch, April 12, 2019.

112.

D. St.

Felix

, “New Shit,” The College Hill Independent, February 28, 2014, available at <https://www.theindy.org/270> (last visited August 3, 2018).

113.

C.R.

Kelly

et al., “Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile Infection: A Randomized Trial,” Annals of Internal Medicine 165, no. 9 (2016): 609-616.

114.

C.H.

Lee

115.

Kao

et al., “Effect of Oral Capsule-vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile Infection: A Randomized Clinical Trial,” JAMA 318, no. 20 (2017): 1985-1993.

116.

Cammarota

et al, “Randomised Clinical Trial: Faecal Microbiota Transplantation by Colonoscopy vs. Vancomycin for the Treatment of Recurrent Clostridium difficile Infection,” Alimentary Pharmacology & Therapeutics 41, no. 9 (2015): 835–843.

117.

Youngster

et al., “Fecal Microbiota Transplant for Relapsing Clostridium difficile Infection Using a Frozen Inoculum From Unrelated Donors: A Randomized, Open-Label, Controlled Pilot Study,” Clinical Infectious Diseases 58, no. 11 (2014): 1515–1522.

118.

van Nood

et al,. “Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile,” New England Journal of Medicine 368 no 5 (2013): 407–415.

119.

M. N.

Quraishi

et al., “Systematic Review with Meta-Analysis: The Efficacy of Faecal Microbiota Transplantation for the Treatment of Recurrent and Refractory Clostridium Difficile Infection,” Alimentary Pharmacology & Therapeutics 46, no. 5 (2017): 479–493.

120.

Moayyedi ,

Yuan ,

Baharith , and

Ford , “Faecal Micro-biota Transplantation for Clostridium difficile Associated Diarrhoea: A Systematic Review of Randomised Controlled Trials,” The Medical Journal of Australia 207, no. 4 (2017): 166–172.

121.

Drekonja

et al., “Fecal Microbiota Transplantation for Clostridium difficile Infection: A Systematic Review,” Annals of Internal Medicine 162, no. 9 (2015): 630-638.

122.

Cammarota ,

Ianiro , and

Gasbarrini , “Fecal Microbiota Transplantation for the Treatment of Clostridium difficile Infection: A Systematic Review,” Journal of Clinical Gastroenterology 48, no. 8 (2014): 693–702.

123.

Cammarota

et al., “Randomised Clinical Trial: Faecal Microbiota Transplantation by Colonoscopy vs. Vancomycin for the Treatment of Recurrent Clostridium difficile Infection,” Alimentary Pharmacology and Therapeutics 41, no. 8 (2017): 835-843.

124.

Youngster

et al., “Oral, Frozen Fecal Microbiota Transplant (FMT) Capsules for Recurrent Clostridium difficile Infection,” BioMed Central Medicine 14, no. 1 (2016): 134.

125.

B.E.

Hirsch

et al., “Effectiveness of Fecal-Derived Microbiota Transfer Using Orally Administered Capsules for Recurrent Clostridium difficile Infection,” BioMed Central Infectious Diseases 15, no. 1 (2015): 191.

126.

Youngster

et al., “Oral, Capsulized, Frozen Fecal Microbiota Transplantation for Relapsing Clostridium difficile Infection,” JAMA 312, no. 17 (2014): 1772-1778.

Where Stool is a Drug: International Approaches to Regulating the use of Fecal Microbiota for Transplantation

Abstract

Get full access to this article

References